

Cleo Delivers Early Progress on Development Program

Highlights

- Selection of biomarkers panel for Cleo's ovarian cancer test-kit has been finalised
- Antibody development has advanced increasing confidence for commercial assay development and upscaling for commercial manufacturing
- The Company is in final stages evaluating four commercial antibody manufacturing partners

MELBOURNE, AUSTRALIA, 9 October, 2023: Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) confirms the delivery of early milestones in its development program targeting the initial surgical triage test market for its simple and accurate blood test.

TEST-KIT BIOMARKERS PANEL FINALISED

Cleo has finalised the selection of biomarkers to be used in its ovarian cancer test-kit, along with completing the development for a prototype of the proprietary scoring algorithm. The performance metrics of the test were evaluated in a clinical study of 334 patients, the results of which are being prepared for publication in a peer-reviewed medical journal. The Company expects the publication outcome to be reported to the market by the end of CY2023. The data cannot be released prior to publication due to the nature of the peer-review process. Concurrently, Cleo is also preparing a further patent application based on the findings.

ANTIBODY DEVELOPMENT

A key objective for the Company is to develop its own antibodies and target proteins which will allow control of supply, quality, cost and high-performance of key reagents that will underpin the consistent and reliable manufacture of test-kits. Cleo can confirm that Surface Plasmon Resonance Analysis has shown that the core antibodies of the CXCL10 active ratio test are binding to their respective targets with high affinity and are suitable for commercial assay development and upscaling in commercial manufacturing. Hybridomas to produce the supporting biomarker antibodies are also well progressed, with expected completion of the full test-kit panel in Q2 CY2024.

Commenting on the early development progress, CLEO Chief Executive, Richard Allman, said:

"The commercial foundation for our ovarian cancer test-kit targeting the initial surgical triage market is coming together quickly. We are running a number of initiatives in parallel which are designed to place the Company in a strong position to achieve key milestones set this financial year."

Cleo Diagnostics Ltd ASX:COV

Level 2, 480 Collins Street, Melbourne, VIC, 3000
ACN 655 717 169 T +61 3 9614 0600 E office@cleodx.com

Directors

Chair and Non-Executive Director: **Adrien Wing**
Chief Executive Officer and Executive Director: **Dr Richard Allman**
Chief Scientific Officer and Executive Director: **Dr Andrew Stephens**
Non-Executive Director and Lead Medical Advisor: **Professor Tom Jobling**
Non-Executive Director: **Lucinda Nolan**

SELECTION PROCESS FOR ANTIBODY MANUFACTURING PARTNER

Cleo is in the late stages of evaluating four commercial antibody manufacturing partners as part of a robust tender process. The evaluation process considers a competitive review of the capabilities of each potential partner to ensure that the partner ultimately selected can deliver commercial product to the standard required by Cleo, which is largely set by regulatory bodies such as the Food and Drug Administration (FDA) and potential customer groups.




Figure 1: Indicative high-level timeline for the commercial development of Cleo's ovarian cancer test-kit for the initial Surgical Triage Test market.

-ENDS-

This ASX announcement was authorised for release on behalf of the CLEO Diagnostics Ltd Board by:
Richard Allman, Chief Executive Officer.

For more information, contact:

Richard Allman
Chief Executive Officer
+613 9614 0000
office@cleodx.com

Elvis Jurcevic
Investor Relations
+614 08 268 271
ej@cleodx.com



Forward Looking Statements: This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of Cleo and certain of the plans and objectives of Cleo with respect to these items. These forward-looking statements are not historical facts but rather are based on Cleo's current expectations, estimates and projections about the industry in which Cleo operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Cleo, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Cleo cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Cleo only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Cleo will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

About Cleo Diagnostics Ltd [ASX:COV](#)

CleoDX aims to bring to market a simple blood test for the accurate and early diagnosis of ovarian cancer based on the novel patented CXCL10 biomarker, which is produced early and at high levels by ovarian cancers but is largely absent in non-malignant disease. The test aims to distinguish benign from malignant growths in a standard format that will be readily compatible with existing equipment used by diagnostic laboratories worldwide.

The platform is backed by over 10 years of scientific Research & Development at the Hudson Institute of Medical Research, with two clinical studies conducted with over 500 patients. Pursuant to a licence agreement with the Hudson Institute of Medical Research, Cleo has a worldwide exclusive licence to commercialise the intellectual property which underpins its operations and the ovarian cancer tests.

The clinical unmet worldwide need is urgent. An accurate and early detection blood test could shift survivability for ovarian cancer significantly as seen with other cancers. Cleo is advancing the availability of its simple blood test, under a modular execution strategy which is designed to eventually address all ovarian cancer detection markets with specific tests including surgical triage, recurrence, high risk, and early-stage screening.

